Immunocore Holdings Future Growth
Future criteria checks 1/6
Immunocore Holdings is forecast to grow earnings and revenue by 26.6% and 19.6% per annum respectively. EPS is expected to grow by 25.6% per annum. Return on equity is forecast to be -183.1% in 3 years.
Key information
26.6%
Earnings growth rate
25.6%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 19.6% |
Future return on equity | -183.1% |
Analyst coverage | Good |
Last updated | 23 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 330 | -141 | -127 | -86 | 11 |
12/31/2025 | 304 | -112 | -105 | -88 | 15 |
12/31/2024 | 286 | -89 | -52 | -11 | 16 |
12/31/2023 | 249 | -55 | -2 | 3 | N/A |
9/30/2023 | 234 | -66 | 14 | 21 | N/A |
6/30/2023 | 231 | -63 | 20 | 26 | N/A |
3/31/2023 | 205 | -52 | 11 | 17 | N/A |
12/31/2022 | 174 | -53 | -51 | -49 | N/A |
9/30/2022 | 114 | -62 | -55 | -54 | N/A |
6/30/2022 | 82 | -112 | -96 | -94 | N/A |
3/31/2022 | 53 | -156 | -134 | -133 | N/A |
12/31/2021 | 36 | -180 | -144 | -143 | N/A |
9/30/2021 | 37 | -150 | -137 | -135 | N/A |
6/30/2021 | 39 | -139 | -111 | -110 | N/A |
3/31/2021 | 42 | -116 | -83 | -78 | N/A |
12/31/2020 | 41 | -101 | -88 | -84 | N/A |
9/30/2020 | 37 | -105 | -91 | -86 | N/A |
6/30/2020 | 34 | -109 | -137 | -131 | N/A |
3/31/2020 | 33 | -120 | -146 | -141 | N/A |
12/31/2019 | 34 | -138 | -142 | -136 | N/A |
12/31/2018 | 30 | -91 | -26 | -21 | N/A |
12/31/2017 | 19 | -66 | -107 | -82 | N/A |
12/31/2016 | 20 | -29 | N/A | -45 | N/A |
12/31/2015 | 17 | 20 | N/A | -26 | N/A |
9/30/2014 | 10 | -9 | N/A | 65 | N/A |
9/30/2013 | 3 | -6 | N/A | 18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6YG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6YG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6YG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6YG's revenue (19.6% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 6YG's revenue (19.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6YG is forecast to be unprofitable in 3 years.